|
|
|
|
|
|
|
|
|
|
|
|
|
22.05.26 - 13:03
|
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss (GlobeNewswire EN)
|
|
|
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.05.26 - 12:24
|
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates (PBR)
|
|
|
Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate
The post Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
18.05.26 - 17:24
|
Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers with Alexis Christoforous:
- NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas.
- Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs.
- Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker's phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update. (Source: Bloomberg)...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
